Table 3.
Individual laboratory, clinical, and imaging results nominally associated with EAA (p<0.05)
| EAD† | EAA† | Odds ratio (95% CI) | p | |
|---|---|---|---|---|
|
| ||||
| Laboratory | ||||
|
| ||||
| Triglycerides (mg/dl) | 128.3 (83.8) | 158.3 (122.8) | 1.07 (1.01, 1.13) ‡ | 0.02 |
| High-density lipoprotein (mg/dl) | 59.7 (18.6) | 53.4 (17.0) | 0.88 (0.77, 0.99) § | 0.04 |
| Total neutrophils (k/mcl) | 3.7 (1.3) | 4.1 (1.6) | 1.26 (1.09, 1.47) | 0.002* |
| Total neutrophils (% WBC) | 58.8 (9.3) | 60.6 (10.1) | 1.02 (1, 1.04) | 0.05 |
| Neutrophil:lymphocyte ratio (k/mcL) | 2.1 (1.0) | 2.4 (1.2) | 1.21 (1, 1.48) | 0.05 |
| White blood cell count | 6.1 (1.7) | 6.6 (2.0) | 1.18 (1.05, 1.33) | 0.005 |
| Albumin (g/dL) | 4.43 (0.30) | 4.39 (0.30) | 0.42 (0.20, 0.87) | 0.02 |
| Glomerular filtration rate (mL/min/1.73 m2) based on MDRD equation | 90.3 (23.0) | 85.3 (19.6) | 0.989 (0.979, 0.999) | 0.03 |
| Uric acid | 5.0 (1.2) | 5.5 (1.4) | 1.29 (1.08, 1.54) | 0.005 |
|
| ||||
| Clinical | ||||
|
| ||||
| History of hypertension, n (%) | 52 (26.7) | 70 (37.2) | 1.7 (1.09, 2.67) | 0.02 |
| Body mass index | 27.8 (6.3) | 30.7 (8.1) | 1.06 (1.03, 1.1) | 0.0001* |
| Waist circumference (cm) | 91.3 (15.3) | 99.2 (18.7) | 1.02 (1.01, 1.04) | 0.0002* |
| Avg daily number of steps in first 30 days | 8558 (3674) | 7786 (3599) | 0.91 (0.85, 0.98) ‖ | 0.009 |
| Hand-grip strength | 72.5 (23.0) | 84.5 (25.9) | 1.014 (1.001, 1.026) | 0.03 |
| Selection for high-risk lung cancer cohort, n (%) | 13 (6.7) | 28 (14.9) | 2.58 (1.3, 5.4) | 0.009 |
| Selection for high-risk CVD cohort, n (%) | 34 (17.4) | 51 (27.1) | 2.02 (1.22, 3.39) | 0.007 |
|
| ||||
| Imaging | ||||
|
| ||||
| Average RNFL thickness (μm) | 93.1 (11.8) | 89.8 (12.6) | 0.979 (0.961, 0.996) | 0.02 |
| RNFL superior quad thickness (μm) | 115.3 (18.3) | 111.3 (19.4) | 0.988 (0.976, 0.999) | 0.04 |
Except where indicated, the results are expressed as the mean (SD). Odds ratios (ORs) from a logistic regression model adjusted for sex; ORs >1 indicate an increase in epigenetic age acceleration with an increase in the variable; ORs <1 indicate a decrease in epigenetic age acceleration with an increase in the variable.
Variables with false discovery rate (FDR) q-value< 0.1
Age acceleration categories are determined using ± 5-year cutoffs.
OR and confidence interval (CI) are for an increase of 25 mg/dl.
OR and CI are for an increase of 10 mg/dl.
OR and CI are for an increase of 1000 steps/day.
CVD, cardiovascular disease; MDRD, Modification of Diet in Renal Disease; RNFL, retinal nerve fiber layer, WBC, white blood cell.